Company: GRCE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001140361-25-041804
Chunk: 10

Company: Grace Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Item 8
Chunk 10
---

     
      (940) 
      (1,756) 

      Ending balance
     
      201 
      2,603 
   
   The
warrant liability was determined based on the fair value of 2023 Common
Warrants at the issue date and the reporting dates using the Black-Scholes
model with the following assumptions.  The 2023 Common Warrants  expired on October 21, 2025, which was the 60th day after the date of the acceptance by
the FDA of an NDA for the Company's product candidate GTx-104.                   September 30, 2025        March 31, 2025        Risk-free interest rate     4.2%   4.18%     Share price    $2.98   $2.28      Expected warrant life     0.06    1.14      Dividend yield     0%   0%     Expected volatility     29.79%   74.26%   
   The weighted average fair values of the 2023 Common Warrants were determined to be $0.08 and $0.45 per 2023 Common Warrant as of September 30, 2025, and March 31, 2025, respectively. The risk-free interest rate at the issue date and on the reporting date of September 30, 2025 was based on the interest rate corresponding to the U.S. Treasury rate issue with a remaining term equal to the expected term of the 2023 Common Warrants. The expected volatility was based on the historical volatility for the Company.  
   As of September 30, 2025 and March 31, 2025, the balance of derivative warrant liabilities from related parties was $169 and $952, respectively. 

   6. Stock-based compensation

   2024 Equity Incentive Plan

   At the Annual and Special Meeting of Shareholders on September 30, 2024, the Company’s shareholders approved the Acasti Pharma Inc. 2024 Equity Incentive Plan (the “2024 Plan”) which became effective on the date of the Domestication. The 2024 Plan replaced the Acasti Pharma Inc. Stock Option Plan and the Acasti Pharma Inc. Equity Incentive Plan (the “Prior Plans”). The